NAD+ augmentation therapy
NAD+ augmentation therapy has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Jan 27, 2026: “The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation”.
1 paper studies it3 findingsUpdated
See all 1 papers on NAD+ augmentation therapy
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“Blood NAD increased slowly, plateauing after approximately two weeks of treatment”
1 of its findings points the other way.
- 1 lab in 1 country
- 1 finding against
- Funders: Dam Foundation and 5 more
- 3 of 3 findings with company ties
- Human trial1
Studies in people
1 study gave NAD+ augmentation therapy to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
up: Increases blood NAD+ concentration up: Increases cerebral NAD+ down: Decreases blood NAD+ concentration | Trialapproximately two weeks to plateau | 6 peopleBothAfter treatment discontinuation | iScience, Jan 27, 2026 |
What did studies of NAD+ augmentation therapy find?
2Studies of NAD+ augmentation therapy measured 2 outcomes: blood NAD+ concentration and cerebral NAD+.
Blood NAD+ concentration
downin humans1upin humans1
1 study
Blood NAD+ concentration
downin humans1upin humans1
NAD+ augmentation therapy decreases blood NAD+ concentration in humans after treatment discontinuation.
“declined with similarly slow kinetics following treatment discontinuation”
Human trialafter treatment discontinuationoral NAD precursorsbloodn = 6
iScience
NAD+ augmentation therapy increases blood NAD+ concentration in humans.
“Blood NAD increased slowly, plateauing after approximately two weeks of treatment”
Human trialoral NAD precursorsblood1,200 mg/dayapproximately two weeks to plateaun = 6
iScience
Cerebral NAD+
upin humans1
1 study
Cerebral NAD+
upin humans1
NAD+ augmentation therapy increases cerebral NAD+ in humans.
“Cerebral NAD levels increased measurably after four weeks of treatment”
Human trialoral NAD precursorsbrain1,200 mg/dayfour weeksn = 6
iScience